Trending NewsTrending NewsTop-Rated StocksTop-RatedNASDAQ:CLYM Climb Bio (CLYM) Stock Price, News & Analysis $16.55 -1.29 (-7.21%) As of 01:13 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Climb Bio Stock (NASDAQ:CLYM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Climb Bio alerts:Sign Up Key Stats Today's Range$16.46▼$17.8050-Day Range$11.34▼$17.8452-Week Range$1.54▼$18.33Volume608,220 shsAverage Volume940,706 shsMarket Capitalization$950.80 millionP/E RatioN/ADividend YieldN/APrice Target$23.08Consensus RatingBuy Company Overview Climb Bio Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need. At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling. This integrated system enables rapid identification, optimization and high-throughput screening of novel protein candidates, accelerating the transition from target validation to preclinical development while maintaining stringent quality and manufacturability criteria. Climb Bio has assembled a portfolio of preclinical programs that leverage its platform to generate next-generation biologics in immuno-oncology and related disease areas. The company is advancing these assets through lead optimization and IND-enabling studies, with a view toward first-in-human clinical trials. By focusing on modalities that can modulate immune responses and tumor microenvironments, Climb Bio aims to create differentiated therapeutic candidates with broad applicability. Headquartered in the greater Boston area, a major hub for life science innovation, Climb Bio operates dedicated research laboratories and maintains a leadership team with extensive experience in biopharmaceutical R&D and strategic partnerships. Looking ahead, the company plans to expand its pipeline through collaborations with academic institutions and industry partners, positioning its platform to address additional disease targets and serve global markets.AI Generated. May Contain Errors. Read More Climb Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreCLYM MarketRank™: Climb Bio scored higher than 53% of companies evaluated by MarketBeat, and ranked 485th out of 917 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingClimb Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 12 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialClimb Bio has a consensus price target of $23.08, representing about 29.4% upside from its current price of $17.84.Amount of Analyst CoverageClimb Bio has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Climb Bio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Climb Bio are expected to decrease in the coming year, from ($0.84) to ($1.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Climb Bio is -21.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Climb Bio is -21.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioClimb Bio has a P/B Ratio of 4.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Climb Bio's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.51% of the float of Climb Bio has been sold short.Short Interest Ratio / Days to CoverClimb Bio has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in Climb Bio has recently increased by 7.38%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldClimb Bio does not currently pay a dividend.Dividend GrowthClimb Bio does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.41 News SentimentClimb Bio has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Climb Bio this week, compared to 4 articles on an average week.Search InterestOnly 6 people have searched for CLYM on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows5 people have added Climb Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Climb Bio insiders have not sold or bought any company stock.Percentage Held by Insiders2.60% of the stock of Climb Bio is held by insiders.Percentage Held by Institutions69.76% of the stock of Climb Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Climb Bio's insider trading history. Receive CLYM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Climb Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CLYM Stock News HeadlinesClimb Bio (CLYM) Advances Phase 2 Trial In China, Is The Valuation Already Priced In?3 hours ago | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Climb Bio (CLYM) and Longeveron (LGVN)August 22, 2026 | theglobeandmail.comTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 is orchestrating what analyst Porter Stansberry calls a total U.S. money reset, bypassing conventional legal channels under the guise of national security. The last time America reset its currency - under Nixon in the 1970s - it created an average of 1,300 new millionaires a day for over 50 years. Stansberry has identified three asset categories connected to Trump's initiative that could surge, plus his single top investment move.August 26 at 1:00 AM | Porter & Company (Ad)Wedbush Reiterates Outperform Rating for Climb Bio (NASDAQ:CLYM)August 21, 2026 | americanbankingnews.comClimb Bio (NASDAQ:CLYM) Reaches New 1-Year High - Here's What HappenedAugust 19, 2026 | americanbankingnews.comClimb Bio (NASDAQ:CLYM) Shares Up 8.2% - Time to Buy?August 16, 2026 | americanbankingnews.comClimb Bio Advances Phase 2 Renal Disease TrialAugust 14, 2026 | tipranks.comTruist Financial Sticks to Their Buy Rating for Climb Bio (CLYM)August 14, 2026 | theglobeandmail.comSee More Headlines CLYM Stock Analysis - Frequently Asked Questions How have CLYM shares performed this year? Climb Bio's stock was trading at $4.00 at the beginning of 2026. Since then, CLYM stock has increased by 346.0% and is now trading at $17.84. How were Climb Bio's earnings last quarter? Climb Bio, Inc. (NASDAQ:CLYM) issued its earnings results on Thursday, August, 6th. The company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.21) by $0.03. When did Climb Bio IPO? Climb Bio (CLYM) raised $80 million in an initial public offering (IPO) on Thursday, August 5th 2021. The company issued 6,400,000 shares at a price of $12.50 per share. Who are Climb Bio's major shareholders? Top institutional shareholders of Climb Bio include Braidwell LP (5.40%), BlackRock Inc. (4.11%), ADAR1 Capital Management LLC (1.43%) and Parkman Healthcare Partners LLC (0.98%). Insiders that own company stock include Ra Capital Management, LP and Emily Pimblett. View institutional ownership trends. How do I buy shares of Climb Bio? Shares of CLYM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/06/2026Today8/26/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (12m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 CLYM's financial health is in the Green zone, according to TradeSmith. CLYM has been in this zone for over 12 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CLYM Previous SymbolNASDAQ:CLYM CIK1768446 Webclimbbio.com Phone866-857-2596FaxN/AEmployees9Year FoundedN/APrice Target and Rating Average Price Target for Climb Bio$23.08 High Price Target$35.00 Low Price Target$18.00 Potential Upside/Downside+39.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($0.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$59.85 million Net MarginsN/A Pretax MarginN/A Return on Equity-31.79% Return on Assets-30.79% Debt Debt-to-Equity RatioN/A Current Ratio31.45 Quick Ratio31.45 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.17 per share Price / Book3.97Miscellaneous Outstanding Shares57,440,000Free Float55,943,000Market Cap$951.78 million OptionableN/A Beta0.08 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:CLYM) was last updated on 8/26/2026 by MarketBeat.com Staff. From Our PartnersA $382 trillion migration and the position no one is talking aboutTrump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...Awesomely | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredTrump Unleashes "Banned" American FuelA newly reopened American mine holds a fuel source so potent that one pound can generate as much energy as 16,...Monument Traders Alliance | SponsoredFree Stock Pick: The Company First in Line for America’s New Super FuelThe U.S. Army and Department of Energy are launching Project Janus - a high-priority initiative ordered by Pre...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Climb Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Climb Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
